RAB-010

RAB-010 is an investigational oral cyclic peptide being developed by RabPharma for the treatment of osteoporosis. The drug candidate is engineered using RabPharma's proprietary technology platform, which is designed to overcome the inherent challenges of peptide delivery, such as low oral bioavailability and rapid enzymatic degradation. By utilizing a cyclic structure, RAB-010 aims to achieve greater metabolic stability and improved absorption compared to linear peptide counterparts. Currently in the preclinical stage (specifically the hit-to-lead phase), RAB-010 is intended to provide a more convenient, non-injectable therapeutic option for patients requiring bone-building or bone-preserving treatments. While the specific molecular target has not been publicly disclosed, the program focuses on modulating bone metabolism to increase bone mineral density.